{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:57:34Z","timestamp":1775685454108,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaccas.2026.107027","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:34:23Z","timestamp":1771936463000},"page":"107027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bortezomib-Induced Myocarditis in a Patient With Multiple Myeloma"],"prefix":"10.1016","volume":"31","author":[{"given":"Adriana","family":"Dom\u00ednguez-Linares","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Karen","family":"Nieto-Dolores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Garcia-Cardenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8347-9523","authenticated-orcid":false,"given":"Alfonso","family":"Gonzalez-Trejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"Ayala-Bustamante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo Armando","family":"Valencia-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Vi\u00f1as-Mendieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-8457","authenticated-orcid":false,"given":"Enrique","family":"Ruiz-Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4820-1325","authenticated-orcid":false,"given":"Nilda","family":"Espinola-Zavaleta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jaccas.2026.107027_bib1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jaccas.2026.107027_bib2","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/med.21476","article-title":"Comprehensive review of cardiovascular toxicity of drugs and related agents","volume":"38","author":"Mlad\u011bnka","year":"2018","journal-title":"Med Res Rev"},{"issue":"1-2","key":"10.1016\/j.jaccas.2026.107027_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11010-016-2846-3","article-title":"Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation","volume":"424","author":"De Salvi Guimar\u00e3es","year":"2017","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"10.1016\/j.jaccas.2026.107027_bib4","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/cancers12092540","article-title":"Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects","volume":"12","author":"Pancheri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jaccas.2026.107027_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jaccas.2026.107027_bib6","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.2353\/ajpath.2010.090690","article-title":"Cardiotoxicity of the anticancer therapeutic agent bortezomib","volume":"176","author":"Nowis","year":"2010","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.jaccas.2026.107027_bib7","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/cancers12082203","article-title":"Targeting NF-\u03baB signaling for multiple myeloma","volume":"12","author":"Wong","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jaccas.2026.107027_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jaccas.2026.107027_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","article-title":"Management of immune checkpoint inhibitor\u2013induced myocarditis","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"3","key":"10.1016\/j.jaccas.2026.107027_bib10","article-title":"Myocarditis: diagnostic modalities and treatment options","volume":"17","author":"Thilakaratne","year":"2025","journal-title":"Cureus"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926001725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926001725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:55:01Z","timestamp":1775681701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084926001725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666084926001725"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.107027","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib-Induced Myocarditis in a Patient With Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.107027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"107027"}}